

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/105886 A2

(51) International Patent Classification⁷: A61K 38/17,
G01N 33/68, A61P 9/10 // C07K 14/705

(21) International Application Number: PCT/SE03/01012

(22) International Filing Date: 16 June 2003 (16.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0201844-8 17 June 2002 (17.06.2002) SE
60/388,747 17 June 2002 (17.06.2002) US

(71) Applicant (for all designated States except US):
CARTELA AB [SE/SE]; Biomedical Center, I 12,
SE-221 84 Lund (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): LUNDGREN-ÅKER-
LUND, Evy [SE/SE]; Trollsjövägen 165, S-237 33 Bjärred
(SE).

(74) Agents: ALBIHNS MALMÖ AB et al.; P.O. Box 4289,
S-203 14 Malmö (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND USES OF THE INTEGRIN ALPHA 10 CHAIN, FOR PREVENTING PROGRESSION OF ATH-
EROSCLEROSIS PLAQUE FORMATION

(57) Abstract: An antigen indicative of the presence of atherosclerotic plaque is provided. The antigen is used in a method for slowing or arresting progression and/or effecting regression of atherosclerotic plaque in a mammal, comprising administering to the mammal a binding agent having binding sites specific for said antigen of said mammal. Also included are methods for diagnosing a mammal who has a risk of developing atherosclerosis, comprising determining the amount of said antigen. Moreover, uses of said antigen for detection and diagnosing atherosclerosis is provided.

WO 03/105886 A2